These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1198 related articles for article (PubMed ID: 36799940)

  • 1. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: A target to modulate cardiovascular risk?
    Dozio E; Vianello E; Malavazos AE; Tacchini L; Schmitz G; Iacobellis G; Corsi Romanelli MM
    Int J Cardiol; 2019 Oct; 292():218-224. PubMed ID: 31023563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.
    Zhao F; Zhou Q; Cong Z; Hang K; Zou X; Zhang C; Chen Y; Dai A; Liang A; Ming Q; Wang M; Chen LN; Xu P; Chang R; Feng W; Xia T; Zhang Y; Wu B; Yang D; Zhao L; Xu HE; Wang MW
    Nat Commun; 2022 Feb; 13(1):1057. PubMed ID: 35217653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
    Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
    Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.
    Roed SN; Nøhr AC; Wismann P; Iversen H; Bräuner-Osborne H; Knudsen SM; Waldhoer M
    J Biol Chem; 2015 Jan; 290(2):1233-43. PubMed ID: 25451942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.
    Knerr PJ; Mowery SA; Douros JD; Premdjee B; Hjøllund KR; He Y; Kruse Hansen AM; Olsen AK; Perez-Tilve D; DiMarchi RD; Finan B
    Mol Metab; 2022 Sep; 63():101533. PubMed ID: 35809773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
    Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
    Mayendraraj A; Rosenkilde MM; Gasbjerg LS
    Peptides; 2022 May; 151():170749. PubMed ID: 35065096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
    Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
    J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
    Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
    Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
    Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
    PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.
    Regmi A; Aihara E; Christe ME; Varga G; Beyer TP; Ruan X; Beebe E; O'Farrell LS; Bellinger MA; Austin AK; Lin Y; Hu H; Konkol DL; Wojnicki S; Holland AK; Friedrich JL; Brown RA; Estelle AS; Badger HS; Gaidosh GS; Kooijman S; Rensen PCN; Coskun T; Thomas MK; Roell W
    Cell Metab; 2024 Jul; 36(7):1534-1549.e7. PubMed ID: 38878772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.
    Leuthardt AS; Boyle CN; Raun K; Lutz TA; John LM; Le Foll C
    Eur J Pharmacol; 2023 Sep; 955():175912. PubMed ID: 37454968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
    Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Epicardial Fat Expresses Glucagon-Like Peptide 1 and 2 Receptors Genes.
    Iacobellis G; Camarena V; Sant DW; Wang G
    Horm Metab Res; 2017 Aug; 49(8):625-630. PubMed ID: 28514806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus.
    Smith C; Patterson-Cross R; Woodward O; Lewis J; Chiarugi D; Merkle F; Gribble F; Reimann F; Adriaenssens A
    Appetite; 2022 Jul; 174():106022. PubMed ID: 35430298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue.
    Kagdi S; Lyons SA; Beaudry JL
    J Endocrinol; 2024 Jun; 261(3):. PubMed ID: 38579777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
    Campbell JE
    Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
    Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
    Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.